Innovation in Phytotherapy: Is a New Regulation the Feasible Perspective in Europe?

Abstract

Classical multicomponent preparations mostly derived from traditional usages in Western and Eastern phytotherapy have been under-evaluated for a long time as potential new pharmaceutical products. The regulatory scenario, in particular at the European level, has only recently considered these aspects proposing harmonized guidelines for the pharmaceutical registration of traditional herbal products. Nevertheless, a specific regulation for innovative products based on the combination of precious knowledge arising from traditional usages and modern scientific advancements is still missing. In this paper, we propose a critical review of the current situation with the specific aim of contributing to create a more favorable regulatory environment for the pharmaceutical registration of new and innovative herbal medicinal products.

Key words

herbal medicinal products - phytotherapy - innovative herbal medicaments

• References

• 1 Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-477
• 2 Morrow JK, Tian L, Zhang S. Molecular networks in drug discovery. Crit Rev Biomed Eng 2010; 38: 143-156
• 3 Gertsch J. Botanical drugs, synergy and network pharmacology: forth and back to intelligent mixtures. Planta Med 2011; 77: 1086-1098
• 4 Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I. A natural history of botanical therapeutics. Metabolism 2008; 57: S3-S9
• 5 Ramawat KG. Herbal drugs: ethnomedicine to modern medicine. Berlin, Heidelberg: Springer-Verlag; 2009
• 6 Silano V, Coppens P, Larrañaga-Guetaria A, Minghetti P, Roth-Ehrang R. Regulations applicable to plant food supplements and related products in the European Union. Food Funct 2011; 2: 710-719
• 7 Bilia AR. Herbal medicinal products versus botanical-food supplements in the European market: state of art and perspectives. Nat Prod Commun 2015; 10: 125-131
• 8 Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. J Chromatogr A 2015; 1382: 136-164
• 9 Bilia AR. Science meets regulation. J Ethnopharmacol 2014; 158: 487-494
• 10 European Medicines Agency. Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products. EMA/HMPC/71049/2007, Rev. 2; 2015. Available at. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/04/WC500185353.pdf Accessed February 22, 2016
• 11 Knöss W, Chinou I. Regulation of medicinal plants for public health – European community monographs on herbal substances. Planta Med 2012; 78: 1311-1316
• 12 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Botanical Drug Development Guidance for Industry, Revision 1: August 2015 (Pharmaceutical Quality/CMC). Available at. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458484.pdf Accessed February 22, 2016
• 13 Schmidt BM, Ribnicky DM, Lipsky E, Raskin I. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol 2007; 3: 360-366
• 14 Fürst R, Zündorf I. Evidence-based phytotherapy in Europe: where do we stand?. Planta Med 2015; 81: 962-967